Producing Monoclonal Antibody Patents (Class 435/70.21)
-
Patent number: 8158365Abstract: An antibody that reacts with 2-O-desulfated acharan sulfate, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The antibody that reacts with 2-O-desulfated acharan sulfate can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to 2-O-desulfated acharan sulfate.Type: GrantFiled: April 27, 2007Date of Patent: April 17, 2012Assignee: Seikagaku CorporationInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto, Yeong Shik Kim
-
Patent number: 8158386Abstract: A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.Type: GrantFiled: September 23, 2010Date of Patent: April 17, 2012Inventors: Li-Te Chin, Shu-Ching Hsu
-
Patent number: 8153767Abstract: It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By using aflatoxin B2 or its derivative as a hapten compound, an antibody, which shows the same reactivity to individual aflatoxin analogs and is highly tolerant to organic solvents, is obtained. Then, a detection/concentration/purification means and an immunological detection means with the use of the above antibody are constructed. The detection means thus constructed achieves a high sensitivity and excellent quantification properties.Type: GrantFiled: November 13, 2007Date of Patent: April 10, 2012Assignee: HORIBA, Ltd.Inventors: Mikiko Uchigashima, Shiro Miyake, Hiroshi Yamashita
-
Patent number: 8133983Abstract: The present invention provides binding molecules, such as human binding molecules, that bind to and stimulate the human OX40-receptor. The invention also provides nucleic acids encoding such binding molecules. Methods for producing such binding molecules are also provided by the present invention. The binding molecules and nucleic acids are useful in the stimulation of human T-cells and can be used to enhance antigen-specific immune responses.Type: GrantFiled: March 23, 2009Date of Patent: March 13, 2012Assignee: Crucell Holland B.V.Inventors: Alexander Berthold Hendrik Bakker, Pauline Marie Louise Meester-Rood, Adrianus Quirinus Bakker
-
Patent number: 8124079Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR.Type: GrantFiled: December 20, 2010Date of Patent: February 28, 2012Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia
-
Publication number: 20120045437Abstract: Monoclonal antibodies against LRP6 and that block the Wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed.Type: ApplicationFiled: February 18, 2011Publication date: February 23, 2012Inventors: Jian-Xing Ma, Kyungwon Lee, Ying Chen
-
Publication number: 20120039911Abstract: The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.Type: ApplicationFiled: January 28, 2009Publication date: February 16, 2012Applicant: Korea Research Institute of Bioscience and BiotechInventors: Young Woo Park, Jae Won Jeon, Joon-Goo Jung, Hye In Choi, Myung-ho Sohn, Ho youn Kim, Mi-La Cho, Young-Soon Jang, Ji-Hun Moon, Ji Hyun Park
-
Publication number: 20120039904Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: January 18, 2011Publication date: February 16, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventor: Tsuguo KUBOTA
-
Patent number: 8105602Abstract: The present invention relates to antibodies, and antigen-binding fragments thereof, specific for urokinase-type plasminogen activator receptor (uPAR) and uses thereof for the treatment or prevention of cancer. In particular, the antibodies of the invention are specific for a particular epitope on uPAR. These antibodies interfere with uPAR signaling. Such antibodies are used in diagnostic and therapeutic methods, particularly against cancer.Type: GrantFiled: December 7, 2007Date of Patent: January 31, 2012Assignee: Tactic Pharma, LLCInventors: Graham Parry, Andrew P. Mazar
-
Patent number: 8093010Abstract: The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules.Type: GrantFiled: October 29, 2009Date of Patent: January 10, 2012Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Patent number: 8093018Abstract: The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More specifically, the above antibody is a domino antibody that specifically recognizes and binds to an antigen-binding first antibody, or an antibody-unlocking antibody that specifically recognizes and binds to a free first antibody.Type: GrantFiled: May 18, 2009Date of Patent: January 10, 2012Assignees: Otsuka Pharmaceutical Co., Ltd., Tokyo University of ScienceInventors: Takachika Azuma, Hisao Takizawa
-
Patent number: 8071336Abstract: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.Type: GrantFiled: February 12, 2010Date of Patent: December 6, 2011Assignee: Genzyme CorporationInventors: John M. McPherson, Tim Edmunds, Qun Zhou
-
Publication number: 20110287454Abstract: This invention provides improved methods for production of monoclonal antibodies against a protein of interest. The present methods are based on immunization of an animal with a fusion protein between a protein of interest and a Th2 cytokine such as IL-4, IL-5, IL-13 and IL-31.Type: ApplicationFiled: May 25, 2011Publication date: November 24, 2011Applicant: CORNELL UNIVERSITYInventor: Bettina Wagner
-
Patent number: 8062867Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: GrantFiled: April 6, 2010Date of Patent: November 22, 2011Assignee: Epitomics, Inc.Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
-
Patent number: 8062866Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: November 13, 2009Date of Patent: November 22, 2011Assignee: Femta Pharmaceuticals, Inc.Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
-
Patent number: 8058405Abstract: The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: GrantFiled: July 10, 2009Date of Patent: November 15, 2011Assignee: Probiodrug (AG)Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
-
Publication number: 20110268750Abstract: The present invention concerns a chimeric polypeptide comprising several polypeptide domains, which is capable of being secreted in association with membrane vesicles and in particular exosomes. The present invention also concerns a polypeptide constituted by one of said domains for the secretion of a peptide or polypeptide of interest in association with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and of polynucleotides coding for said polypeptides for the production of immunogenic compositions based on exosomes or based on DNA or for screening protein interactions.Type: ApplicationFiled: March 18, 2009Publication date: November 3, 2011Applicants: Universite Montpellier 2 Sciences et Techniques, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Robert Zaine EI Abiddine Mamoun, Bernadette Nadine Trentin, Michel Vidal
-
Publication number: 20110263825Abstract: It is intended to provide a monoclonal antibody having a growth inhibitory activity against a cell having a human CD20 antigen which is produced by using, as immunogens, a human B cell line expressing the human CD20 antigen and a cell line originating in a non-human animal, which is different from an animal to be immunized and has been transformed with human CD20 DNA, and a monoclonal antibody obtained by chimerization or humanization of the above-described monoclonal antibody. These monoclonal antibodies show biological activities suitable for using as drugs.Type: ApplicationFiled: September 6, 2007Publication date: October 27, 2011Applicant: OSAKA UNIVERSITYInventors: Susumu Uchiyama, Kiichi Fukui
-
Patent number: 8043852Abstract: The present invention provides a monoclonal antibody displaying excellent specificity against heparan sulfate saccharide chains for the analysis of heparan sulfate saccharide chains specific to dentin. The invention also provides a method of evaluating reproductive dentin using the monoclonal antibody. The anti-heparan sulfate monoclonal antibody reacts against dentin-derived heparan sulfate and in particular the anti-heparan sulfate monoclonal antibody reacts strongly and specifically with uncalcified predentin regions. In the method of evaluating dentin, the antibody is reacted against an isolated dentin-derived sample and the reaction is used in order to evaluate the development of dentin.Type: GrantFiled: August 19, 2008Date of Patent: October 25, 2011Assignee: Hitachi, Ltd.Inventors: Akiko Hisada, Ryosuke Takahashi, Hiroko Hanzawa
-
Patent number: 8039599Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.Type: GrantFiled: June 2, 2000Date of Patent: October 18, 2011Assignee: Novartis AGInventors: Richard Sedrani, Valerie Quesniaux
-
Publication number: 20110243949Abstract: The present invention relates to a composition comprising D-peptides or antibodies for use as a therapeutic and/or for disease prevention, wherein a) the D-peptides interact with an amyloid peptide and b) the antibodies bind to the D-peptide from a) and additionally to the amyloid peptide from a).Type: ApplicationFiled: November 17, 2009Publication date: October 6, 2011Applicants: Forschungszentrum Juelich GmbH, Heinrich-Heine-UniversitaetInventors: Dieter Willbold, Carsten Korth, Andreas Mueller-Schiffmann, Susanne Aileen Funke
-
Patent number: 8030026Abstract: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.Type: GrantFiled: February 24, 2009Date of Patent: October 4, 2011Assignee: Abbott LaboratoriesInventors: Susan E. Brophy, Bailin Tu, Joan D. Tyner, Lowell J. Tyner, legal representative, Dagang Huang, Robert N. Ziemann
-
Publication number: 20110236931Abstract: Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts.Type: ApplicationFiled: April 14, 2009Publication date: September 29, 2011Applicant: HUMAN BIOMOLECULAR RESEARCH INSTITUTEInventors: John R. Cashman, Mary T. MacDonald
-
Publication number: 20110229475Abstract: The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.Type: ApplicationFiled: April 16, 2008Publication date: September 22, 2011Inventors: Stephanie Jane Clegg, Eric Dobrzynski, Jonathan H. Ellis, Volker Germaschewski, Alexis Paul Godillot, Zdenka Ludmila Jonak, Alan P. Lewis, John R. White
-
Patent number: 8021856Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.Type: GrantFiled: August 9, 2005Date of Patent: September 20, 2011Assignee: Roche GlycArt AGInventors: Pablo Umaña, Joël Jean-Mairet, James E. Bailey, M. Sean Bailey, legal representative
-
Patent number: 8017748Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.Type: GrantFiled: April 18, 2006Date of Patent: September 13, 2011Assignee: Micromet AGInventors: Tobias Raum, Julia Hepp (Nee Henckel), Eva Vieser (Nee Krinner), Silke Petsch (Nee Mittelstrass), Steven Zeman, Andreas Wolf, Sandra Bruckmaier
-
Patent number: 8008043Abstract: Provided are processes for culturing cells derived from embryonic retinoblast cells immortalized by adenovirus E1 sequences, such as PER.C6® cells, to improve product yields from such cells. Feed strategies for such cells and cultures with very high cell densities are provided, resulting in high yields of products, such as recombinant antibodies.Type: GrantFiled: July 26, 2010Date of Patent: August 30, 2011Assignee: Crucell Holland B.V.Inventor: Christopher A. Yallop
-
Patent number: 8007792Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.Type: GrantFiled: March 20, 2009Date of Patent: August 30, 2011Assignees: INSERM, Biomerieux SAInventors: Marie-Anne Petit, Colette Jolivet-Reynaud, Christian Trepo
-
Publication number: 20110200614Abstract: The present invention is directed to diagnostic tools and therapies using antibodies to Bacillus anthracis. Specifically, the present invention is directed to a B. anthracis-specific monoclonal antibody that binds to the EA1 antigen (corresponding to the eag gene) of the S-layer (surface layer) of spores. This monoclonal antibody may be used in a variety of applications, including to specifically detect and diagnose B. anthracis. Preferably, antibodies are monoclonal and bind to a surface protein, such as EA1 protein, on the spores of B. anthracis, and not to spores of either B. cereus or B. thuringiensis. Antibodies can be incorporated into detection kits using, for example, colloidal particle based lateral flow detection system. Such detection kits can distinguish anthrax spores from non-pathogenic varieties of spores. In addition, the invention is directed to B.Type: ApplicationFiled: November 16, 2009Publication date: August 18, 2011Inventors: Beverly Lynn Mangold, Jennifer Lynn Aldrich, Thomas W. O'Brien
-
Publication number: 20110195456Abstract: The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.Type: ApplicationFiled: April 20, 2011Publication date: August 11, 2011Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Patent number: 7993864Abstract: The present invention provides a homogeneous assay for identifying an antibody producing cell producing an antibody which binds to a selected antigen comprising: a) providing a population of antibody producing cells; b) incubating said population of antibody producing cells with a selected antigen and a labeled anti-antibody antibody, wherein said anti-antibody antibody is capable of distinguishing cells producing an antibody which binds to the selected antigen from those cells which do not; and c) identifying an antibody producing cell capable of producing an antibody which binds to the selected antigen.Type: GrantFiled: December 1, 2003Date of Patent: August 9, 2011Assignee: UCB Pharma S.A.Inventors: Derek Thomas Brown, Lisa Butler, Karen Dorothy Cromie, Meryn Ruth Griffiths, Alastair David Griffiths Lawson, Daniel John Lightwood
-
Patent number: 7993641Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: GrantFiled: October 16, 2006Date of Patent: August 9, 2011Assignee: BTG International LimitedInventors: Herman Waldmann, Mark Frewin
-
Patent number: 7994289Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: GrantFiled: June 18, 2003Date of Patent: August 9, 2011Assignee: BTG International LimitedInventors: Herman Waldmann, Mark Frewin
-
Patent number: 7985842Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: November 24, 2008Date of Patent: July 26, 2011Assignee: Immunogen Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Publication number: 20110178182Abstract: A method of producing a nanostructure composition from a solid powder is disclosed. The method comprises: (a) heating the solid powder, thereby providing a heated solid powder; (b) immersing the heated solid powder in a liquid in the presence of a gas medium, the liquid being colder than the heated powder, and (c) irradiating the cold liquid, the heated solid powder and the gas medium by electromagnetic radiation selected such that nanostructures are formed from particles of the solid powder and a stable gas phase is formed from the gas medium.Type: ApplicationFiled: August 20, 2008Publication date: July 21, 2011Inventor: Eran Gabbai
-
Patent number: 7968093Abstract: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodies, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.Type: GrantFiled: December 17, 2009Date of Patent: June 28, 2011Assignee: ImClone LLCInventor: Dale L Ludwig
-
Patent number: 7968688Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: January 8, 2009Date of Patent: June 28, 2011Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans
-
Publication number: 20110145938Abstract: Method for generating monoclonal antibodies that recognize progenitor cells. Said method comprises immunization of an Armenian hamster with neurospheres obtained from olfactory bulb cells from a 13.5-day mouse embryo and subsequent selection of the antibodies by means of neurosphere flow cytometry in the presence of propidium iodide. The antibodies thus obtained may be of use in the enrichment of cell cultures in progenitor cells, primarily neural progenitor cells.Type: ApplicationFiled: April 29, 2009Publication date: June 16, 2011Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASInventors: Augusto Silva González, Ignacio Del Valle Torres, Leyre GarcĂa Benzaquen
-
Patent number: 7960145Abstract: The compositions and methods of the present invention comprise the efficient and effective presentation of antigens to the appropriate components of the immune system resulting in the production of species-specific antibodies in vitro. In general, these compositions comprise one or more antigenic components together with a colloidal metal, optionally combined with derivatized PEG (polyethylene glycol) or other agents. The invention also comprises novel cytokine cocktails for generating desired antibodies.Type: GrantFiled: November 10, 2008Date of Patent: June 14, 2011Assignee: CytImmune Sciences, Inc.Inventors: Giulio F. Paciotti, Ramadevi Raghunandan, Marja S. Huhta, Lawrence Tamarkin
-
Patent number: 7960518Abstract: The present invention provides human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from Enterococcus.Type: GrantFiled: June 5, 2007Date of Patent: June 14, 2011Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Robert Arjen Kramer, Cornelis Adriaan De Kruif
-
Patent number: 7955807Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.Type: GrantFiled: November 10, 2006Date of Patent: June 7, 2011Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
-
Patent number: 7943742Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: GrantFiled: July 10, 2006Date of Patent: May 17, 2011Assignee: Biogen Idec MA Inc.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Patent number: 7943334Abstract: The present invention provides an immunological detection method that can detect milk allergens, allergens of albumen, flour, buckwheat and peanut with high sensitivity in foods containing these allergens regardless they are denatured/native, and a detection kit to be used therefor. It is a method for detecting allergens by using 2 or more monoclonal antibodies recognizing native and denatured milk allergens, native and denatured albumen allergens, native and denatured flour allergens, native and denatured buckwheat allergens, and native and denatured peanut allergens, using asl casein which is the main protein of milk casein, ?-lactoglobulin which is the main protein of whey, ovalubumin and ovomucoid which are main proteins of albumen, gliadin which is the main protein of flour, protein with a molecular weight of 24 kDa and 76 kDa which are main proteins of buckwheat, and Ara h1 which is the main protein of peanut as an index.Type: GrantFiled: March 4, 2005Date of Patent: May 17, 2011Assignee: Prima Meat Packers, Ltd.Inventors: Masanobu Akimoto, Shigeki Katou, Makoto Namioka
-
Patent number: 7939282Abstract: Compositions and methods for detecting sepsis by contacting a subject-derived sample with a ligand that binds to GRK and determining the concentration of GRK in the sample. An increase in the concentration of GRK compared to that of a normal, healthy control sample indicates that the subject from which the sample is obtained is suffering from or at risk of developing sepsis.Type: GrantFiled: October 20, 2005Date of Patent: May 10, 2011Assignee: Rhode Island HospitalInventors: Loren D. Fast, Yow-Pin Lim
-
Patent number: 7939077Abstract: The present invention relates to an antibody against FGF-8, particularly a humanized antibody against FGF-8 and the antibody fragment thereof, a DNA sequence encoding the above antibody or the antibody fragment, a vector comprising the DNA sequence and a host cell transformed by the vector, a production process of the above antibody or the antibody fragment using the host cell, and a therapeutic agent and a diagnostic agent for cancer using the antibody or the antibody fragment.Type: GrantFiled: June 28, 2002Date of Patent: May 10, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Kazuyasu Nakamura, Maiko Hirota, Naoki Shimada
-
Patent number: 7935794Abstract: The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease.Type: GrantFiled: April 23, 2009Date of Patent: May 3, 2011Assignee: Pfizer Ltd.Inventor: Nicholas Pullen
-
Patent number: 7923221Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.Type: GrantFiled: April 13, 1995Date of Patent: April 12, 2011Assignees: Genentech, Inc, City of HopeInventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
-
Patent number: 7919273Abstract: The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), result in improved therapeutic properties, such as decreased dissociation rates, improved CDC activity, improved apoptosis, improved B-cell depletion and improved therapeutic efficacy at very low dosages.Type: GrantFiled: July 21, 2009Date of Patent: April 5, 2011Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Chien-Hsing Chang, Hans J. Hansen
-
Patent number: 7919255Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.Type: GrantFiled: June 17, 2004Date of Patent: April 5, 2011Assignee: Otago Innovation LimitedInventors: Timothy Charles Ramsey Prickett, Eric Arnold Espiner, Arthur Mark Richards, Timothy Grant Yandle, Michael Gary Nicholls
-
Patent number: RE42324Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-Fc?RI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.Type: GrantFiled: April 9, 2010Date of Patent: May 3, 2011Assignee: Phadia ABInventors: Sylvia Laffer, Erik Hogbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Grönlund, Rudolf Valenta